Company: GRCE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001140361-25-041804
Chunk: 47

Company: Grace Therapeutics, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Item 8
Chunk 47
---
, and are incorporated by reference into this Item 5.

   (c)

 During the three months ended September 30, 2025, no director or officer of the Company adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K. 

     Item 6.

     Exhibits

    Exhibit No.
     
    Description

      3.1

      Certificate of Incorporation of Grace Therapeutics, Inc. (incorporated by referenced to Exhibit 3.1 on the Current Report on Form 8-K filed with the Commission on October 7, 2024)

      3.2

      Certificate of Amendment to the Certificate of Incorporation of Grace Therapeutics, Inc. (incorporated by referenced to Exhibit 3.1 on the Current Report on Form 8-K filed with the Commission on October 28, 2024)

      3.3

      Bylaws of Grace Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 on the Current Report on Form 8-K filed with the Commission on October 28, 2024)

    10.1*† 
     
    Amendment No. 1 to Letter
Agreement by and between Prashant Kohli and the Company, dated November 12,
2025 

    10.2*†
     
    Letter Agreement by and
between Robert J. DelAversano and the Company, dated November 12, 2025

    10.3*†
     
    Letter Agreement by and
between Amresh Kumar and the Company, dated November 12, 2025

    10.4*†
     
    Letter Agreement by and
between Carrie D’Andrea and the Company, dated November 12, 2025

    10.5*†
     
    Letter Agreement by and
between R. Loch Macdonald and the Company, dated November 12, 2025

      31.1*

      Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934

      31.2*

      Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities